The survey also showed that many believe value-based care is being gamed and that chances that it will be successful are small.
Weaning U.S. healthcare off fee-for-service payment to value-based care arrangements that reward cost-effective care has been talked about for years. But walking that talk has been a halting, sort of effort for a tangled set of reasons, not the least of which is the ingrained, staying power of fee for service
The Managed Healthcare Executive® State of the Industry confirmed that the move toward valued-based has been modest and revealed some jaded views.
Asked to rate their own organization’s shift away from fee for service to value-based care, 12% of the 450 respondents indicated they hadn’t started, 27% indicated beginning and 27% indicated midway. Only 17% rated their organization as being mainly in value-based arrangements.
About one-third (34%) of the respondents indicated agreement with the statement that value-based care arrangements and payment models are “admirable but the chances of success are small.” A large proportion (41%) agree with the statement that they have been “gamed by some organizations to increase profits and revenues.”
There is some optimism, albeit tethered. A large if minority group of the respondents (37%) said the value-based arrangements were on the right track but needed adjustment. Abou the same proportion (39%) said the arrangements don’t provide enough of an incentive to lower healthcare spending.
Accountable care organizations (ACOs) and bundled or episodic payment arrangements have gotten a great deal of attention. But 39% of the respondents to the survey said pay-for-performance incentives were most likely to be successful in improving outcomes and reducing costs this year. Only 20% thought ACOs would and only 18% thought bundled payments would.
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen
Disappointment Over the Uptake of Humira Biosimilars | Asembia 2024
April 30th 2024In a discussion with Managed Healthcare Executive, Cate Lockhart, Pharm.D., Ph.D., executive director, Biologics and Biosimilars Collective Intelligence Consortium, talks about the disappointment surrounding the uptake of Humira biosimilars.
Read More
The Debate About Ending Interchangeability Designation for Biosimilars | Asembia 2024
April 30th 2024In a discussion with Managed Healthcare Executive, Cate Lockhart, Pharm.D., Ph.D., executive director, Biologics and Biosimilars Collective Intelligence Consortium, talks about whether or not she favors ending interchangeability designation for biosimilars.
Read More